Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galidesivir - BioCryst Pharmaceuticals

Drug Profile

Galidesivir - BioCryst Pharmaceuticals

Alternative Names: BCX-4430

Latest Information Update: 12 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioCryst Pharmaceuticals
  • Developer BioCryst Pharmaceuticals; National Institute of Allergy and Infectious Diseases; Utah State University
  • Class Antivirals; Purine nucleosides; Pyrimidine nucleosides; Pyrroles; Pyrrolidines; Small molecules
  • Mechanism of Action RNA replicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ebola virus infections; Marburg virus disease; Yellow fever
  • Preclinical Zika virus infection
  • No development reported Middle East respiratory syndrome coronavirus

Most Recent Events

  • 13 May 2019 BioCryst Pharmaceuticals plans a phase I trial for Yellow fever (IV) in Brazil (NCT03891420)
  • 20 Sep 2018 Galidesivir is still in phase I clinical trials for Ebola virus infections (In volunteers) in United Kingdom (IM)
  • 20 Sep 2018 Galidesivir is still in phase I clinical trials for Marburg virus disease (In volunteers) in United Kingdom (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top